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Abstract
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) is a transient process occurring during developmental
stages and carcinogenesis, characterized by phenotypic and molecular alterations, resulting in increased invasive
and metastatic capabilities of cancer cells and drug resistance. Moreover, emerging evidence suggests that EMT
is associated with increased enrichment of cancer stem–like cells in neoplastic tissues. We interrogated the mo-
lecular alterations occurring in breast cancer using proposed EMT markers such as E-cadherin, vimentin, epider-
mal growth factor receptor (EGFR), platelet-derived growth factor (PDGF) D, and nuclear factor κB (NF-κB) to
decipher their roles in the EMT and breast cancer progression. METHODS: Fifty-seven invasive ductal adenocar-
cinomas of the breast were assessed for the expression of E-cadherin, vimentin, EGFR, NF-κB, and PDGF-D using
immunohistochemical analysis. Tumors were categorized into three groups: A (ER+, and/or PR+, HER-2/neu−),
B (ER+, and/or PR+, HER-2/neu+), and C (triple-negative: ER−, PR−, and HER-2/neu−). Immunostained slides
were microscopically evaluated and scored using intensity (0, 1+, 2+, and 3+) and percentage of positive cells,
and data were statistically analyzed. RESULTS:Membranous E-cadherin was positive in all 57 cases (100%), whereas
cytoplasmic E-cadherin was predominantly positive in groups B and C compared with group A (21%, 7%, and 0%,
respectively). All group A cases were negative for vimentin and EGFR. There was statistically significant increased
expression of vimentin (P < .0002), EGFR (P < .0001), and NF-κB (P < .02) in triple-negative cases when compared
with groups A and B. CONCLUSIONS: Vimentin, EGFR, and NF-κB were significantly increased in triple-negative
tumors, which is consistent with the aggressiveness of these tumors. These markers could be useful as markers
for EMT in breast cancers and may serve as predictive markers for designing customized therapy in the future.
Translational Oncology (2011) 4, 222–226
Introduction
Epithelial-to-mesenchymal transition (EMT) is a transient process
occurring during carcinogenesis that is characterized by alterations
resulting in increased invasive and metastatic capabilities of cancer
cells, and it has also been proposed to play a key role in drug resistance
[1,2]. During the acquisition of EMT phenotype, the cancer cells
undergo phenotypic and molecular alterations representing mesen-
chymal differentiation. The phenotypic changes include transforma-
tion of the cuboidal/cobblestone morphology to elongated, spindle,
fibroblastic-type morphology [1,2]. The molecular changes include
loss of specialized epithelial cell adhesion molecules like cadherins
and acquisition of mesenchymal markers like vimentin.
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The acquisition of EMT phenotype eventually leads to increased
motile function of the cells consistent with invasion and metastasis.
These elongated spindle-shaped cells interact with the neighboring
cells only to a limited extent (and only at focal points) and display a
“front-back” polarity [3]. Physiologically, EMT-like changes have
been described during embryogenesis [4], in adult skin (as cells
move from the inner germinal layer to the surface), and in intestine
(as cells move from the crypts to the villi) [3]. However, these are
coordinated and organized unlike EMT seen in cancers. EMT also
plays a key role in inflammation, fibrosis, and wound healing where
there is loss of cell adhesion, increased cell motility, and reversible
dedifferentiation [3].
The gene regulatory programs controlling EMT regulate cell ad-
hesion molecules and their signaling pathways and have emerged as
important determinants of tumor cell invasion and metastasis [5].
EMT is reversible and is regulated by the interplay of several extra-
cellular signals, growth factors, their effectors and transcription factors
[6]. Moreover, EMT has also been proposed to play a critical role in
“cancer stem cells” or cancer stem–like cells (CSCs) [7], although
these cellular processes are not synonymous [6]. Recently, salinomy-
cin has been used to selectively kill CSCs induced by treating breast
cancer cells with transforming growth factor β1 documenting the
acquisition of EMT phenotype [8], and these results suggest that the
killing of drug-resistant EMT-type cells (CSCs) could be achieved by
novel therapeutics.
Breast cancer has a diverse clinical spectrum. Despite similarities in
the histologic presentation at the time of disease diagnosis, their clin-
ical behaviors, including time to disease progression and metastasis,
cannot be predicted with certainty. Therefore, there is a dire need to
identify which patients would respond to therapeutic regimens and
who would not. Identifying the aggressive phenotype such as the
presence of EMT-type cells, one would be able to predict the behav-
ior of cancer cells. This would likely assist in predicting the clinical
behavior of tumors and, consequently, design better and customize
therapy to cure breast cancer in patients with tumors for which there
is no targeted therapy.
Recent advances in the treatment of breast cancer have led to a
significant improvement in survival of patients diagnosed with hor-
mone receptor– and/or HER-2–positive disease. However, tumors
that are lacking the expression of estrogen receptor (ER), progester
one receptor (PR), and HER-2, the so-called triple-negative sub-
group have a relatively aggressive clinical course, with early develop-
ment of visceral metastases and a poor long-term prognosis [9]. As
a group, the triple-negative breast carcinoma cases have a poor
prognosis. Hence, they are an area of interest for the development
of novel targeted agents, although specific targets have not been
fully validated.
By uncovering the molecular mechanisms that govern EMT in
breast cancer, one could prevent metastasis by converting an invasive
phenotype to a noninvasive one using target-specific therapeutics.
Thus, inactivation of EMT signaling pathways by novel approaches
could potentially be useful for preventing cancer progression in the
near future [10]. A better understanding of the biologic mechanism
of these EMT molecular changes may help to identify new targets for
breast cancer therapy, which would be useful for designing personal-
ized medicine. The aim of the present study was to investigate the
expression patterns of proteins associated with the EMT to elucidate
intracellular cell signaling in the tumor milieu and provide novel diag-
nostic and therapeutic markers.
Materials and Methods
The study was conducted in the Department of Pathology, Karmanos
Cancer Institute at Wayne State University School of Medicine, De-
troit, MI. At the outset, an institutional review board approval and
a waiver of consent for a retrospective review of archived material
were obtained.
Study Cohort
On retrospective review of archived paraffin-embedded invasive
ductal carcinomas of the breast, a total of 57 cases were selected for
the study. Tumors were categorized into three groups: A (ER+, and/or
PR+, HER-2/neu−), B (ER+, and/or PR+, HER-2/neu+), and C
(triple-negative: ER−, PR−, HER-2/neu−).
Histologic Evaluation
In each case, the histopathologic slides were reviewed microscop-
ically, and a representative tumor block was selected. In each block,
4-μm-thick tumor tissue sections were obtained from positively
charged glass slides and interrogated for EMT markers including
E-cadherin, vimentin, nuclear factor κB (NF-κB; nuclear and activated
p65 subunit), epidermal growth factor receptor (EGFR), and platelet-
derived growth factors (PDGF) D.
Immunohistochemical Analysis
Tissue sections were immunohistochemically stained using specific
antibodies for E-cadherin, vimentin, NF-κB, EGFR, and PDGF-D.
These markers were chosen based on existing evidence from our lab-
oratory, documenting the role of these markers in the acquisition of
EMT [11]. Standard laboratory protocols according to the laboratory
manual were established using the avidin-biotin complex staining
procedure. Initial trials used the manufacturer’s suggested specimen
preparation and staining conditions. Each protocol was optimized for
antigen retrieval, antibody dilution, and incubation conditions as
outlined in Table 1. A known positive tissue for the antigen of in-
terest was used to titer the antibody and, subsequently, was stained
with each investigative case for the current study. Immunohisto-
chemical staining was performed as follows: tissue sections were de-
paraffinized, hydrated to phosphate-buffered saline buffer (pH 7.4)
and pretreated with hydrogen peroxide (3%) for 10 minutes to re-
move endogenous peroxidase. This was followed by antigen retrieval
through steam bath for 20 minutes with EDTA. The slides were then
incubated with the primary antibody at ambient temperature and
washed with phosphate-buffered saline followed by incubation with
biotin-labeled secondary antibody for 30 minutes at room temperature.
Finally, slides were developed with 0.05% 3′,3-diaminobenzidine
Table 1. Antibody Details for Immunohistochemistry.
Antibody Source Dilution
E-cadherin Zymed 1:50
Vimentin Ventana Prefilled
EGFR Zymed Automated
PDGF-D Zymed 1:200
NF-κB Cell Signaling 1:10
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tetrahydrochloride and then counterstained with Mayer hematoxylin,
dehydrated, and mounted.
Slide Evaluation
Immunostained slides were blindly evaluated by a pathologist under
a transmission light microscope. Areas of highest staining density were
identified for evaluating the expression in tumors.
Microscopic Scoring of Expression
Expression was scored for each antibody separately and semi-
quantitatively by assessing the stain localization, intensity, and the
percentage of stained cells in the tumors. Stain localization was clas-
sified as nuclear, cytoplasmic, and membranous. Staining intensity
was scored as 0 (no staining), 1+ (weak), 2+ (medium), or 3+
(strong). The percentage of stained cells was categorized into the
following: 1, 0% to 10% stained cells; 2, 11% to 50% stained cells;
3, 50% stained cells or greater. The final score was obtained by mul-
tiplying the two scores. Cases with a score of 0 to 4 were classified as
negative, and those with a final score of 5 to 9 were classified as pos-
itive. Statistical analyses were performed with the SPSS for Windows
software (version 13.0; SPSS, Inc, Chicago, IL).
Results and Discussion
Membranous E-cadherin expression was positive in all 57 cases
(100%), whereas cytoplasmic E-cadherin staining was more prevalent
in the more aggressive B and C groups with 21% (5/24) and 7% (1/14)
cytoplasmic positive staining, respectively. Of all group A cases (n =
19), none (0%) were negative for vimentin and EGFR, 15 (79%) were
positive for PDGF-D, and 6 (32%) were positive for nuclear NF-κB
(Figure 1; Table 2). In all group B cases (n = 24), 18 (75%) were
positive for PDGF-D, 10 (42%) were positive for NF-κB, 6 (25%)
were positive for vimentin, and 2 (8%) were positive for EGFR. In
group C cases (triple-negative; n = 14), there was increased expres-
sion of vimentin in 9 cases (64%), of EGFR in 14 cases (100%), of
NF-κB in 11 cases (79%), and of PDGF-D in 9 cases (64%). We
found increased expression of vimentin (P < .0002), EGFR (P < .0001),
and NF-κB in triple-negative breast cancer specimens, which was sta-
tistically highly significant (P < .02) when compared with groups A
and B.
Breast cancer is a heterogeneous disease that consists of multiple
molecular subtypes. The presence of hormone receptors ER and
PR and overexpression of human EGFR-2 (HER-2) is of central im-
portance in the therapeutic decision-making process for patients with
breast cancer. Apart from predicting response to therapy, these fac-
tors may also determine the likelihood of disease relapse. Hormone
receptor–positive tumors have been considered to have favorable out-
come because of their response to endocrine manipulations such as
tamoxifen, aromatase inhibitors, or ovarian ablation. Triple-negative
breast cancer (TNBC) is a term that has been used to describe a bi-
ologically diverse group of breast tumors that are lacking in the ex-
pression of ER, PR, and HER-2. Tumors with a triple-negative
phenotype tend to have poor prognosis and, unlike their hormone
receptor or HER-2–positive counterparts, lack targeted therapeutics.
As a result, the interest in this aggressive TNBC from both clinicians
and scientists has grown exponentially.
Figure 1. Microphotographs of representative examples of immunohistochemical staining of EMT markers in breast cancer cases
showing (A) vimentin cytoplasmic positivity in group C, (B) EGFR membranous and cytoplasmic positivity in group C, (C) NF-κB nuclear
positivity in group A, and (D) PDGF-D cytoplasmic positivity in group C. Original magnification, ×400.
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The EMT phenomenon is triggered by the interplay of several
extracellular signals; many secreted soluble factors, growth factors,
their effectors, and many transcription factors including PDGF,
Notch, and NF-κB [6]. The translational relevance of these EMT
markers in evaluating aggressiveness of human breast cancers speci-
mens has not been well investigated, and thus in the present study,
we interrogated EMT markers such as E-cadherin, vimentin, NF-κB,
EGFR, and PDGF-D in breast cancer specimens. Cases were divided
based on their prognosis and aggressiveness into the highly aggressive
triple-negative tumors versus the relatively innocuous ER-, PR-,
HER-2–positive tumors. EMT markers (vimentin, EGFR, and
NF-κB) were found to be significantly higher in triple-negative breast
tumors (known aggressive tumors) but not PDGF-D, and our find-
ings are consistent with similar findings reported in the literature [12].
Vimentin is a cytoplasmic intermediate filament protein found to
be the major component of the cytoskeleton. Our findings of its
association with clinically aggressive behavior of breast tumors are
also consistent with previous studies [13–15]. Conversely, Heatley
et al. [16] have demonstrated that vimentin expression did not in-
versely predict patient survival. The association of vimentin with
clinically aggressive behavior of tumors has been explained based
on the correlation of vimentin’s expression with lack of steroid recep-
tors and poor differentiation of cancer [9]. During EMT, the cell
intermediate filament status changes from a keratin-rich network,
which connects to adherens junctions and hemidesmosomes, to a
vimentin-rich network connecting to focal adhesions [17]. Sarrio
et al. [18] have suggested that vimentin-positive cells may have a phe-
notypic plasticity prone to undergo EMT, and although transient,
they involve modulation of a number of EMT genes.
The EGFR is a member of the ErbB family of receptor tyrosine
kinases. The high incidence of EGFR expression in triple-negative
tumors in our study is similar to findings by other authors [19,20].
The EGFR positivity has been related to a less favorable response to
chemotherapy and poorer survival, indicating that it can serve as a
valuable tool for selecting appropriate treatment regimens for patients
with TNBC [19]. The activation of EGFR leads to the activation of
NF-κB, which could be useful for predicting tumor aggressiveness.
NF-κB is a transcription factor that is well known to contribute to
the acquisition of EMT and tumor cell invasion [3]. High NF-κB
expression found in the triple-negative breast cancer cases in our study
is similar to those of previous authors [21,22]. Genes induced by the
NF-κB activation could serve as therapeutic targets of triple-negative
breast cancers, and to that end, inactivation of NF-κB pathway by
many natural agents has been reported [23–26], including recent
findings of plumbagin, suggesting that natural agents could be useful
for the prevention and/or treatment of aggressive breast cancer espe-
cially the TNBCs [27].
PDGF-D is an important regulator of cell proliferation, transfor-
mation, invasion, and metastasis in human cancer [10]. It has been
linked with several human malignancies [28] and has also been
shown to play an important role in the processes of EMT [29,30]
by causing changes in cellular morphology concomitant with loss
of E-cadherin, gain of vimentin, increase in tumor growth, and in-
creased cancer cell invasion and angiogenesis [10]. Moreover, forced
overexpression of PDGF-D in PC prostate cancer cells showed the
acquisition of stem cell characteristics, suggesting the role of
PDGF-D in self-renewal and tumor cell aggressiveness [31]. In the
present study, we found that PDGF-D was not significantly higher
in triple-negative breast tumors when compared with the other prog-
nostic groups. A review of literature reveals that similar studies have
not been previously done in human breast cancer tissues; however, in
breast cancer cell lines, PDGF-D has been demonstrated to play an
important role in tumor aggressiveness [28]. Several reasons might be
behind the lack of correlation between tumor aggressiveness and
PDGF-D positivity in our study. First, the use of IHC to evaluate
protein levels does not always reflect the structure or functionality of
the protein. Second, the small size of the patient cohort would intro-
duce an element of bias in this evaluation. Third, technical aspects
such as the clone of antibody used and antigen retrieval methods
might have played a part in this disparity and needs further clarifica-
tion in future IHC studies.
In summary, based on our findings, we conclude that the expres-
sion of vimentin, EGFR, and NF-κB were significantly increased in
human TNBCs. The higher expression of these markers seen in triple-
negative tumors may explain the different biologic behavior of these
tumor types. Therefore, vimentin, EGFR, and NF-κB may have the
potential to be used as markers for EMT in breast cancers, and tar-
geted inactivation of these markers could be useful for designing per-
sonalized medicine, which would be the future to make an impact on
improving the overall survival of patients diagnosed with TNBCs.
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